233 related articles for article (PubMed ID: 16291408)
1. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
[TBL] [Abstract][Full Text] [Related]
2. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
Hamilton T; Menter A; Caro I; Compton P; Sobell J; Papp KA
Drug Saf; 2008; 31(8):715-26. PubMed ID: 18636790
[TBL] [Abstract][Full Text] [Related]
3. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab.
Pincelli C; Henninger E; Casset-Semanaz F
Arch Dermatol Res; 2006 Dec; 298(7):329-38. PubMed ID: 17021768
[TBL] [Abstract][Full Text] [Related]
4. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
[TBL] [Abstract][Full Text] [Related]
5. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
6. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
7. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
Toth DP; Papp K; Gratton D
Dermatol Ther; 2008; 21 Suppl 3():S6-14. PubMed ID: 19076630
[TBL] [Abstract][Full Text] [Related]
9. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
11. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
[TBL] [Abstract][Full Text] [Related]
12. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
Ortonne JP; Shear N; Shumack S; Henninger E;
BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
[TBL] [Abstract][Full Text] [Related]
13. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
Papp KA; Camisa C; Stone SP; Caro I; Wang X; Compton P; Walicke PA; Gottlieb AB
J Cutan Med Surg; 2005 Dec; 9(6):313-23. PubMed ID: 16699903
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
Pariser DM; Gordon KB; Papp KA; Leonardi CL; Kwon P; Compton PG; Rundle AC; Walicke PA; Lebwohl M
J Cutan Med Surg; 2005 Dec; 9(6):303-12. PubMed ID: 16699904
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
[TBL] [Abstract][Full Text] [Related]
17. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
[TBL] [Abstract][Full Text] [Related]
18. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
Gottlieb AB; Hamilton T; Caro I; Kwon P; Compton PG; Leonardi CL;
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S154-63. PubMed ID: 16488337
[TBL] [Abstract][Full Text] [Related]
19. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
[TBL] [Abstract][Full Text] [Related]
20. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
